No trial has tested this combination in people. Each compound below has whatever evidence it has, on its own. Putting two or three of them in one vial does not combine their evidence, and no study has looked at what they do together, in what order, or at what cost. Everything on this page about the pairing is a description of what is claimed for it, not a finding.
What is in it
Semax's anxiolytic sibling, developed at the same Russian institute. It is framed as a benzodiazepine alternative without sedation, tolerance or dependence — a claim supported by Russian tri…
- Evidence
- Limited
- Status
- Limited Approval
- Documented risks
- 5 · 3 serious
A well-established medicine in Russia with essentially no Western trial replication. The pharmacology is plausible and the domestic clinical literature is substantial; the problem is that al…
- Evidence
- Limited
- Status
- Limited Approval
- Documented risks
- 5 · 3 serious
Why it is sold this way
The pairing is presented as complementary rather than synergistic: semax for attention, drive and the stroke and cognition indications it is registered for in Russia, selank for anxiety without sedation. Both are reported to act on brain-derived neurotrophic factor, which is the mechanism most often cited for putting them together.
What the combination actually has behind it
Each component is a registered medicine in Russia with its own domestic clinical literature, and each is rated on this site accordingly. That literature is largely Russian-language, frequently small, and has not been replicated to the standard a Western regulator would require. The combination specifically has no trial at all. Taking two compounds that each have modest, single-country evidence does not produce the evidence for the pair.
| Selank |
2/5 Limited
Evidence rating 2 out of 5: Limited
Preclinical work plus scattered human reports, uncontrolled use, or negative trials. |
|---|---|
| Semax |
2/5 Limited
Evidence rating 2 out of 5: Limited
Preclinical work plus scattered human reports, uncontrolled use, or negative trials. |
| The blend | No human trial of the combination exists. The figure that matters for a mixture is its weakest component, which here is 2 of 5. |
What mixing them makes impossible
Both are reported to act partly through the same neurotrophic signalling, so the usual argument that different mechanisms combine safely is weaker here than it looks. Nasal administration also makes exposure harder to reason about than injection: how much of a peptide crosses the nasal mucosa varies with the formulation, the technique and the state of the nose on the day.
Change one thing at a time. This is the most useful rule on the safety page and a fixed mixture breaks it by design. If a blend helps, you cannot say which part helped; if it harms, you cannot say which part harmed, or stop that part alone.
Regulatory status
Approved in Russia; not approved by the FDA or EMA, and not in the FDA compounding record. Material sold outside Russia is not the registered product.
| Semax | Advisory committee recommended Off Category 2 since April 2026 and recommended by the FDA’s advisory committee in July 2026 — but not yet on the 503A bulks list, so not yet lawfully compoundable. |
|---|
The dated record for the compounds this site tracks is on the compounding status page, which is checked against the FDA's own documents rather than against anybody's description of them. A committee recommendation is not FDA action, removal from a list is not permission, and none of it is drug approval.
Related compounds
This page is educational information, not medical advice. It cannot account for your medical history, medications or risk factors. Do not start, stop or change any treatment based on it.